Kirkland & Ellis advises Cinven and Bioclinica, while Latham & Watkins advises Astorg, Nordic Capital, Novo Holdings, and ERT on the merger of Bioclinica with ERT.
Bioclinica sold the stake/assets to ERT as part of a merger on 2020-12-10.
Deal value was 60000000000 (source: AI Estimation) Seller position: significant minority investment; Sector: Life Sciences; Location: Global.
On the seller side, Kirkland & Ellis advised, led by Laura Sullivan, Sean Rodgers, Jud Oswald.
Generated by AI, original source from - Data is in progress
Found it useful? Spread the word.
Kirkland & Ellis advises Cinven and Bioclinica, while Latham & Watkins advises Astorg, Nordic Capital, Novo Holdings, and ERT on the merger of Bioclinica with ERT. | The Sponsor - The Sponsor
